W
Weiwei Tan
Researcher at Pfizer
Publications - 37
Citations - 7402
Weiwei Tan is an academic researcher from Pfizer. The author has contributed to research in topics: Crizotinib & Medicine. The author has an hindex of 16, co-authored 27 publications receiving 6803 citations.
Papers
More filters
Journal ArticleDOI
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak,Yung-Jue Bang,D. Ross Camidge,Alice T. Shaw,Benjamin Solomon,Robert G. Maki,Sai-Hong Ignatius Ou,Bruce J. Dezube,Pasi A. Jänne,Daniel B. Costa,Marileila Varella-Garcia,Woo-Ho Kim,Thomas J. Lynch,Panos Fidias,Hannah Stubbs,Jeffrey A. Engelman,Lecia V. Sequist,Weiwei Tan,Leena Gandhi,Mari Mino-Kenudson,Greg C. Wei,S. Martin Shreeve,Mark J. Ratain,Jeffrey Settleman,James G. Christensen,Daniel A. Haber,Keith D. Wilner,Ravi Salgia,Geoffrey I. Shapiro,Jeffrey W. Clark,A. John Iafrate +30 more
TL;DR: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.
Journal ArticleDOI
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Sai-Hong Ignatius Ou,Yung-Jue Bang,D. Ross Camidge,Benjamin Solomon,Ravi Salgia,Gregory J. Riely,Marileila Varella-Garcia,Geoffrey I. Shapiro,Daniel B. Costa,Robert C. Doebele,Long P. Le,Zongli Zheng,Zongli Zheng,Weiwei Tan,Patricia Stephenson,S. Martin Shreeve,L. Tye,James G. Christensen,Keith D. Wilner,Jeffrey W. Clark,A. John Iafrate +21 more
TL;DR: Crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC, and ROS1 rearrangement defines a second molecular subgroup of NSCLCs for which crizotin ib is highly active.
Journal ArticleDOI
CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib
Daniel B. Costa,Susumu Kobayashi,Shuchi Sumant Pandya,Wee-Lee Yeo,Zhongzhou Shen,Weiwei Tan,Keith D. Wilner +6 more
Journal ArticleDOI
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Sai-Hong Ignatius Ou,Eunice L. Kwak,Christina Siwak-Tapp,Joni Dy,Kristin Bergethon,Jeffrey W. Clark,D. Ross Camidge,Benjamin Solomon,Robert G. Maki,Yung-Jue Bang,Dong Wan Kim,James G. Christensen,Weiwei Tan,Keith D. Wilner,Ravi Salgia,A. John Iafrate +15 more
TL;DR: An NSCLC patient with de novo MET amplification but no ALK rearrangement who achieved a rapid and durable response to crizotinib indicating is also a bona fide MET inhibitor.
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Patricia LoRusso,Smitha S. Krishnamurthi,John J. Rinehart,Lisle Nabell,Lisa Malburg,Paul B. Chapman,Samuel E. DePrimo,Steven Bentivegna,Keith D. Wilner,Weiwei Tan,Alejandro D. Ricart +10 more
TL;DR: The maximum tolerated dose, based on first cycle dose-limiting toxicities, was 15 mg BID continuously, however, 10 and 15mg BID continuous dosing and 10 mg B ID 5 days on/2 days off schedules were associated with delayed development of RVO; thus, further enrollment to this trial was stopped.